Skip to main content

Table 3 Unadjusted measures of abandonment, adherence and persistence, by index oral oncolytic received and pharmacy channel

From: Impact of pharmacy channel on adherence to oral oncolytics

  Erlotinib Imatinib Capecitabine
Characteristica Specialty Traditional Retail Specialty Traditional Retail Specialty Traditional Retail
Number Prescribed Index Oncolytic 4774 10,297 2292 4941 4906 15,156
Abandonment of Index Prescription f   f   f  
 Approved Without Challenges, N (%) 4643 97.3% 9644 93.7% 2271 99.1% 4688 94.9% 4817 98.2% 14,456 95.4%
 Initial Challenge but Overcome, N (%) 66 1.4% 358 3.5% 7 0.3% 157 3.2% 45 0.9% 360 2.4%
 Initial Challenge Unknown if Overcome, N (%)b 3 0.1% 25 0.2% 0 0.0% 3 0.1% 0 0.0% 15 0.1%
 Abandoned, N (%)c 50 1.0% 239 2.3% 11 0.5% 79 1.6% 36 0.7% 286 1.9%
 Unknown, N (%)d 12 0.3% 31 0.3% 3 0.1% 14 0.3% 8 0.2% 39 0.3%
Adherence - Proportion of Days Covered between the First and Last Fill
MPR Mean (SD) 92.1 (14.0)f 89.6 (17.1) 86.8 (18.9)f 82.5 (21.2) 80.7 (20.4)f 70.6 (22.5)
 Number with >1 Fill 3439 7091 2046 4230 3709 10,898
 Adherent, N (%) 2888 84.0%f 5691 80.3% 1527 74.6%f 2813 66.5% 2171 58.5%f 4038 37.1%
Persistencee - Time until Discontinuation of Index Oncolytic (days)
 Number Filling Prescription for Index Oncolytic 4709 10,002 2278 4845 4862 14,816
 Mean (SD) 146.0 (166.7)f 135.8 (169.9) 423.2 (359.0)f 394.5 (354.9) 114.2 (120.2)f 103.2 (115.3)
 Median 89 79 324 292 78 63
 Minimum–Maximum 0–1441 0–1613 0–1622 0–1601 0–1316 0–1397
  1. Note: NDC codes 50242006201, 50242006301, 50242006401, 54569584700, 54569584800, 54868529000, 54868544700, 54868547400 used to identify erlotinib, NDC codes 00004110020, 00004110051, 00004110116, 00004110150, 54569571700, 54868414300-54868414303, 54868526000-54868526009 used to identify capecitabine, NDC codes 00078037366, 00078040105, 00078040134, 00078040215, 00078043815, 54569584600, 54868528900-54868528904, 54868542700-54868542703 used to identify imatinib
  2. Abbreviations: SD standard deviation, N number of patients
  3. aGroup comparisons were made using 2-sided Pearson chi-square for categorical measures and t-test statistics for continuous measures within each index oncolytic population, p-values are presented for comparisons using traditional retail as reference group
  4. bUnable to determine if hurdle overcome because data were censored
  5. cAbandonment measure refers to whether patient was able to successfully fill prescription within 90 days following an initial challenge (if no, prescription was considered abandoned)
  6. dNo information provided regarding the patients first fill status, cannot determine if prescription was filled
  7. eTime until discontinuation (in days) of index oral oncolytic, allowing for a 60 day gap in therapy between the run-out date of the medication and the subsequent fill
  8. f P < 0.001